Lundbeck/Otsuka’s Results For 5HT6 Antagonist In Alzheimer’s Clears Path For Phase III Trials
This article was originally published in PharmAsia News
Executive Summary
Lundbeck announced Jul 17 positive Phase II results for Lu AE58054 as an add-on to donepezil for Alzheimer’s disease, and a Phase III trial with partner Otsuka will go ahead as planned.